We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What's in Store for Perrigo (PRGO) This Earnings Season?
Read MoreHide Full Article
Investors are likely to focus on Perrigo Company plc’s (PRGO - Free Report) plans for growth, after its pending transformation into a pure self-care company later this year on the first-quarter 2021 earnings call.
Perrigo’s earnings performance has been mixed over the trailing four quarters. The company’s earnings beat estimates in three of the last four quarters and missed the same once, delivering an average surprise of 6.44%.
Shares of Perrigo have lost 4.7% so far this year against the industry‘s increase of 9.1%.
In the last reported quarter, Perrigo delivered a negative earnings surprise of 7.92%.
Factors at Play
In the first quarter, the performance of Perrigo’s Consumer Self Care Americas (“CSCA”) and Consumer Self Care International (“CSCI”) segments is expected to have been aided by the products added following the acquisition of Ranir Global Holdings.
Meanwhile, new products have been witnessing significant sales growth.Oral Care assets of High Ridge Brands acquired in April are likely to have boosted sales in the soon-to-be reported quarter. Moreover, the launch of store brand equivalent of over-the-counter Voltaren arthritis pain drug in September 2020 is likely to have brought additional revenues during the quarter.
However, sales of cough/cold products are likely to have been adversely impacted by COVID-19 and dented the top line significantly.
Loss of sales from the recall of albuterol sulfate inhalation aerosol, discontinued products and exited business, especially its Animal Health business sold to PetIQ (PETQ - Free Report) , might have offset the gain from the new products.
The COVID-19 pandemic boosted demand for Perrigo’s certain products in 2020, driving revenues. However, it hurt products of some segments. However, the extent of the impact of the pandemic on the first-quarter results remains to be seen.
Higher sales of new products in the Rx segment and continued moderation of pricing pressure in the generics industry are likely to have driven segment sales. However, discontinued products and lower sales of cough/cold products are likely to have hampered this segment’s revenues.
Meanwhile, the favorable impact cost savings due to ongoing restructuring initiatives and operating expense discipline are likely to have boosted the bottom line.
Investors will likely be keen to know more about the impact of pricing pressure and COVID-19 on the first-quarter earnings call.
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for Perrigo in this reporting cycle. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that is not the case here as you will see below.
Earnings ESP: Perrigo has an Earnings ESP of 0.00%. This is because both the Most Accurate Estimate and the Zacks Consensus Estimate are pegged at 56 cents per share. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Perrigo carries a Zacks Rank #5 (Strong Sell).
Here are two biotech stocks that have the right combination of elements to beat on earnings this time around.
Avenue Therapeutics, Inc. (ATXI - Free Report) has an Earnings ESP of +16.67% and a Zacks Rank #2.
Pacira BioSciences, Inc. (PCRX - Free Report) has an Earnings ESP of +3.80% and a Zacks Rank of 2.
Zacks Top 10 Stocks for 2021
In addition to the stocks discussed above, would you like to know about our 10 best buy-and-hold tickers for the entirety of 2021?
Last year's 2020Zacks Top 10 Stocks portfolio returned gains as high as +386.8%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Image: Bigstock
What's in Store for Perrigo (PRGO) This Earnings Season?
Investors are likely to focus on Perrigo Company plc’s (PRGO - Free Report) plans for growth, after its pending transformation into a pure self-care company later this year on the first-quarter 2021 earnings call.
Perrigo’s earnings performance has been mixed over the trailing four quarters. The company’s earnings beat estimates in three of the last four quarters and missed the same once, delivering an average surprise of 6.44%.
Shares of Perrigo have lost 4.7% so far this year against the industry‘s increase of 9.1%.
In the last reported quarter, Perrigo delivered a negative earnings surprise of 7.92%.
Factors at Play
In the first quarter, the performance of Perrigo’s Consumer Self Care Americas (“CSCA”) and Consumer Self Care International (“CSCI”) segments is expected to have been aided by the products added following the acquisition of Ranir Global Holdings.
Meanwhile, new products have been witnessing significant sales growth.Oral Care assets of High Ridge Brands acquired in April are likely to have boosted sales in the soon-to-be reported quarter. Moreover, the launch of store brand equivalent of over-the-counter Voltaren arthritis pain drug in September 2020 is likely to have brought additional revenues during the quarter.
However, sales of cough/cold products are likely to have been adversely impacted by COVID-19 and dented the top line significantly.
Loss of sales from the recall of albuterol sulfate inhalation aerosol, discontinued products and exited business, especially its Animal Health business sold to PetIQ (PETQ - Free Report) , might have offset the gain from the new products.
The COVID-19 pandemic boosted demand for Perrigo’s certain products in 2020, driving revenues. However, it hurt products of some segments. However, the extent of the impact of the pandemic on the first-quarter results remains to be seen.
Higher sales of new products in the Rx segment and continued moderation of pricing pressure in the generics industry are likely to have driven segment sales. However, discontinued products and lower sales of cough/cold products are likely to have hampered this segment’s revenues.
Meanwhile, the favorable impact cost savings due to ongoing restructuring initiatives and operating expense discipline are likely to have boosted the bottom line.
Investors will likely be keen to know more about the impact of pricing pressure and COVID-19 on the first-quarter earnings call.
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for Perrigo in this reporting cycle. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that is not the case here as you will see below.
Earnings ESP: Perrigo has an Earnings ESP of 0.00%. This is because both the Most Accurate Estimate and the Zacks Consensus Estimate are pegged at 56 cents per share. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Perrigo carries a Zacks Rank #5 (Strong Sell).
You can see the complete list of today’s Zacks #1 Rank stocks here.
Perrigo Company plc Price and EPS Surprise
Perrigo Company plc price-eps-surprise | Perrigo Company plc Quote
Stocks to Consider
Here are two biotech stocks that have the right combination of elements to beat on earnings this time around.
Avenue Therapeutics, Inc. (ATXI - Free Report) has an Earnings ESP of +16.67% and a Zacks Rank #2.
Pacira BioSciences, Inc. (PCRX - Free Report) has an Earnings ESP of +3.80% and a Zacks Rank of 2.
Zacks Top 10 Stocks for 2021
In addition to the stocks discussed above, would you like to know about our 10 best buy-and-hold tickers for the entirety of 2021?
Last year's 2020Zacks Top 10 Stocks portfolio returned gains as high as +386.8%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
AccessZacks Top 10 Stocks for 2021 today >>